Hematologic Malignancy
Monoclonal Immunoglobulin Deposition Disease
CI-CAN-00006049Explore in graph →
HematologicNon-malignant37 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006049Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05184088 | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis(CArdiag) | completed | Phase 3 | 244 | Lantheus Germany GmbHINDUSTRY | 4 | Aug 3, 2026 | clinicaltrials |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis(EMN27) | completed | Phase 2 | 35 | Stichting European Myeloma NetworkNETWORK | 6 | Jul 31, 2026 |
| clinicaltrials |
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03820817 | Rifaximin in Patients With Monoclonal Gammopathy | completed | Phase 1 | 50 | Emory UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07585331 | Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance | completed | — | 250 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04392960 | Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | completed | N/A | 30 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03431896 | Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis(MED-hATTR) | completed | — | 37 | The Cleveland ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT01758042 | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders(BMT) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03499808 | S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | completed | Phase 2 | 43 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02924272 | Ixazomib Rollover Study | completed | Phase 2 | 32 | TakedaINDUSTRY | 11 | Mar 12, 2025 | clinicaltrials |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | completed | Phase 2 | 25 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | completed | Phase 1 | 30 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05260203 | MargheRITA (Remote Intelligence for Therapeutic Adherence)(MargheRITA) | completed | N/A | 124 | Advice Pharma Group srlINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT00520767 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | completed | Phase 2 | 35 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03959358 | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT00224393 | Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 60 | The Cleveland ClinicOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT02158052 | Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease | completed | N/A | 2 | Massachusetts General HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | completed | Phase 1 / Phase 2 | 28 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04937777 | A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe | completed | — | 4,481 | European Myeloma Network B.V.NETWORK | 10 | Sep 27, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT01078454 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | completed | Phase 3 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03886155 | Cardiac Amyloidosis Screening at Trigger Finger Release(CAST) | completed | — | 107 | The Cleveland ClinicOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03923920 | Screening for Systemic Amyloidosis Via the Ligamentum Flavum(ALF) | completed | — | 200 | The Cleveland ClinicOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT02716103 | Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis(MRD) | completed | — | 45 | Boston Medical CenterOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT02207556 | Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial(DUAL) | completed | Phase 2 | 32 | Medical College of WisconsinOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT01083316 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis | completed | Phase 2 | 35 | Boston Medical CenterOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT01570387 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Boston Medical CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT02555969 | Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | completed | — | 56 | Tufts Medical CenterOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01222260 | Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis | completed | Phase 2 | 40 | Columbia UniversityOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00651937 | Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02574676 | Quality of Life (QOL) Registry for Patients With AL Amyloidosis | completed | — | 343 | Prothena Biosciences Ltd.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02791373 | Vinorelbine and Gemcitabine in Myeloma(ViGeM) | completed | Phase 2 | 136 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01677286 | Safety and Effect of Doxycycline in Patients With Amyloidosis | completed | Phase 2 | 25 | Boston UniversityOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials